1-4 of 4
Wilfried Auer
Close
Sort by
Journal Articles

Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.

Wilfried Auer, PhD, Hanspeter Rottensteiner, PhD, Gerald Schrenk, PhD, Werner Hoellriegl, PhD, Alexandra Schiviz, DVM, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Peter L Turecek, PhD, Eva-Maria Muchitsch, PhD
Journal: Blood
Blood (2012) 120 (21): 2233.
https://doi.org/10.1182/blood.V120.21.2233.2233
Published: 2012
Journal Articles

Preclinical Safety of Baxter's Recombinant Factor VIIa

Barbara Dietrich, PhD, Susan Kubik, PhD, Wilfried Auer, PhD, Birgit Reipert, PhD, Frank Horling, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch, PhD
Journal: Blood
Blood (2010) 116 (21): 1417.
https://doi.org/10.1182/blood.V116.21.1417.1417
Published: 2010
Journal Articles

Preclinical Safety of Baxter's Recombinant Factor IX

Barbara Dietrich, PhD, Susan Kubik, PhD, Wilfried Auer, PhD, Kuno Wuersch, PhD, Birgit Reipert, PhD, Frank Horling, PhD, Martin Wolfsegger, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch, PhD
Journal: Blood
Blood (2010) 116 (21): 4654.
https://doi.org/10.1182/blood.V116.21.4654.4654
Published: 2010
Journal Articles

In Vivo Characterization of Recombinant von Willebrand Factor in Dogs With von Willebrand Disease

Peter L. Turecek, Herbert Gritsch, Ludwig Pichler, Wilfried Auer, Bernhard Fischer, Artur Mitterer, Wolfgang Mundt, Uwe Schlokat, Friedrich Dorner, Herm Jan M. Brinkman, Jan A. van Mourik, Hans Peter Schwarz
Journal: Blood
Blood (1997) 90 (9): 3555–3567.
https://doi.org/10.1182/blood.V90.9.3555
Published: 1997